144 related articles for article (PubMed ID: 11118045)
1. Allelic deletions of cell growth regulators during progression of bladder cancer.
Primdahl H; von der Maase H; Christensen M; Wolf H; Orntoft TF
Cancer Res; 2000 Dec; 60(23):6623-9. PubMed ID: 11118045
[TBL] [Abstract][Full Text] [Related]
2. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A.
Møller MB; Kania PW; Ino Y; Gerdes AM; Nielsen O; Louis DN; Skjødt K; Pedersen NT
Leukemia; 2000 May; 14(5):898-904. PubMed ID: 10803523
[TBL] [Abstract][Full Text] [Related]
3. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
[TBL] [Abstract][Full Text] [Related]
4. The gene expression index c-myc x E2F-1/p21 is highly predictive of malignant phenotype in human bronchial epithelial cells.
DeMuth JP; Jackson CM; Weaver DA; Crawford EL; Durzinsky DS; Durham SJ; Zaher A; Phillips ER; Khuder SA; Willey JC
Am J Respir Cell Mol Biol; 1998 Jul; 19(1):18-24. PubMed ID: 9651176
[TBL] [Abstract][Full Text] [Related]
5. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A.
Elnenaei MO; Gruszka-Westwood AM; A'Hernt R; Matutes E; Sirohi B; Powles R; Catovsky D
Haematologica; 2003 May; 88(5):529-37. PubMed ID: 12745272
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical study of the expression of cell cycle regulating proteins at different stages of bladder cancer.
Primdahl H; von der Maase H; Sørensen FB; Wolf H; Ørntoft TF
J Cancer Res Clin Oncol; 2002 Jun; 128(6):295-301. PubMed ID: 12073046
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
8. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
[TBL] [Abstract][Full Text] [Related]
9. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
[TBL] [Abstract][Full Text] [Related]
11. p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy.
Pfister C; Flaman JM; Dunet F; Grise P; Frebourg T
J Urol; 1999 Jul; 162(1):69-73. PubMed ID: 10379742
[TBL] [Abstract][Full Text] [Related]
12. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways.
Goodwin EC; DiMaio D
Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12513-8. PubMed ID: 11070078
[TBL] [Abstract][Full Text] [Related]
13. Combination E2F-1 and p53 gene transfer does not enhance growth inhibition in human squamous cell carcinoma of the head and neck.
Frank DK; Liu TJ; Frederick MJ; Clayman GL
Clin Cancer Res; 1998 Sep; 4(9):2265-72. PubMed ID: 9748148
[TBL] [Abstract][Full Text] [Related]
14. Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma.
Nord H; Segersten U; Sandgren J; Wester K; Busch C; Menzel U; Komorowski J; Dumanski JP; Malmström PU; Díaz de Ståhl T
Int J Cancer; 2010 Mar; 126(6):1390-402. PubMed ID: 19821490
[TBL] [Abstract][Full Text] [Related]
15. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.
Markl ID; Jones PA
Cancer Res; 1998 Dec; 58(23):5348-53. PubMed ID: 9850064
[TBL] [Abstract][Full Text] [Related]
16. Analysis of downstream effectors of p53 on cell growth arrest and apoptosis induced by a temperature-sensitive Val138 mutant.
Wang FJ
J Med Dent Sci; 1998 Jun; 45(2):141-9. PubMed ID: 11186200
[TBL] [Abstract][Full Text] [Related]
17. Molecular control of the cell cycle in cancer: biological and clinical aspects.
Møller MB
Dan Med Bull; 2003 May; 50(2):118-38. PubMed ID: 12812137
[TBL] [Abstract][Full Text] [Related]
18. p27kip1-independent cell cycle regulation by MYC.
Berns K; Martins C; Dannenberg JH; Berns A; te Riele H; Bernards R
Oncogene; 2000 Oct; 19(42):4822-7. PubMed ID: 11039898
[TBL] [Abstract][Full Text] [Related]
19. Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf-1, and Ki-67 in multiple myeloma: correlation with cyclin-D1 immunoreactivity.
Lai R; Medeiros LJ; Wilson CS; Sun NC; Koo C; McCourty A; Brynes RK
Mod Pathol; 1998 Jul; 11(7):642-7. PubMed ID: 9688185
[TBL] [Abstract][Full Text] [Related]
20. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression.
Hiyama H; Iavarone A; LaBaer J; Reeves SA
Oncogene; 1997 May; 14(21):2533-42. PubMed ID: 9191053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
